Literature DB >> 9204957

Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay.

E H Kemp1, D J Gawkrodger, S MacNeil, P F Watson, A P Weetman.   

Abstract

Tyrosinase antibodies recently have been reported to occur frequently in patients with vitiligo. We describe the detection of tyrosinase antibodies in vitiligo patients using in vitro 35S-labeled human tyrosinase in a radioimmunoassay. Of 46 vitiligo sera examined in the assay, five (10.9%) were found to be positive for tyrosinase antibodies. In contrast, 20 control sera and sera from 10 patients with Hashimoto's thyroiditis were negative. Four of the sera positive in the radioimmunoassay were also positive in an ELISA using mushroom tyrosinase as antigen. Absorption studies indicated that pre-incubation with mushroom tyrosinase absorbed out the immunoreactivity of the positive sera in the radioimmunoassay, suggesting cross-reactivity, but this absorption was never complete, indicating that there are tyrosinase antibodies in human sera that do not react with the mushroom protein. There was no obvious association between the presence of tyrosinase antibodies and the age of the patients (range: 22-62 y), their duration of disease (range: 5-20 y), or the type of vitiligo (one segmental, one symmetrical/periorificial, three symmetrical), although the three patients with the highest antibody levels also had an associated autoimmune disorder (one with Graves' disease; two with autoimmune hypothyroidism). The results confirm that tyrosinase autoantibodies are present in the sera of vitiligo patients but at a low frequency. The technique described is sensitive and quantitative and allows the detection of conformational epitopes. It will be useful in longitudinal studies to determine the relation between the clinical features of vitiligo and tyrosinase antibody levels.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9204957     DOI: 10.1111/1523-1747.ep12276556

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  13 in total

1.  Molecular mapping of epitopes on melanocyte-specific protein Pmel17 which are recognized by autoantibodies in patients with vitiligo.

Authors:  E H Kemp; E A Waterman; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.

Authors:  P Agretti; G De Marco; D Sansone; C Betterle; G Coco; A Dimida; E Ferrarini; A Pinchera; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2010-03-22       Impact factor: 4.256

Review 3.  Skin disorders and thyroid diseases.

Authors:  H Niepomniszcze; R H Amad
Journal:  J Endocrinol Invest       Date:  2001-09       Impact factor: 4.256

4.  Tumor immunity and autoimmunity induced by immunization with homologous DNA.

Authors:  L W Weber; W B Bowne; J D Wolchok; R Srinivasan; J Qin; Y Moroi; R Clynes; P Song; J J Lewis; A N Houghton
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

5.  The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo.

Authors:  E Helen Kemp; Elizabeth A Waterman; Brian E Hawes; Kim O'Neill; Raju V S R K Gottumukkala; David J Gawkrodger; Anthony P Weetman; Philip F Watson
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

6.  Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA).

Authors:  E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

7.  Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo.

Authors:  Mitesh Dwivedi; Naresh C Laddha; Kriti Shah; Bela J Shah; Rasheedunnisa Begum
Journal:  J Interferon Cytokine Res       Date:  2013-06-18       Impact factor: 2.607

8.  Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1.

Authors:  E A Waterman; E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

9.  Nonsegmental vitiligo and autoimmune mechanism.

Authors:  Naoki Oiso; Tamio Suzuki; Kazuyoshi Fukai; Ichiro Katayama; Akira Kawada
Journal:  Dermatol Res Pract       Date:  2011-07-26

10.  Association of Angiotensin-Converting Enzyme (ACE) Gene Polymorphism with Inflammation and Cellular Cytotoxicity in Vitiligo Patients.

Authors:  Laila Rashed; Rania Abdel Hay; Rania Mahmoud; Nermeen Hasan; Amr Zahra; Salwa Fayez
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.